The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorBassett Healthcare
About this trial
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Eligibility criteria
Qualifiers
Hospitalized or being hospitalized.
Age >/=18 yr old.
Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician.
Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively).
Disqualifiers
None
Trial design
Treatments tested in this trial
- Piperacillin + Tazobactam
- meropenem
Treatment groups
852 Participants
are divided into 2 treatment groupsSponsors and collaborators
Bassett Healthcare
Lead sponsor
Johns Hopkins University
Collaborator
Patient-Centered Outcomes Research Institute
Collaborator
Source ClinicalTrials.gov